Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery
Primary Purpose
Postoperative Ileus
Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
bisacodyl
glucosemonohydricum
Sponsored by
About this trial
This is an interventional treatment trial for Postoperative Ileus focused on measuring postoperative ileus, colorectal surgery, bisacodyl, laxatives
Eligibility Criteria
Inclusion Criteria:
- elective colorectal resection
- age >18 years
Exclusion Criteria:
- preoperatively planned stoma formation
- emergency surgery
- pregnancy
- known hypersensitivity for bisacodyl
Sites / Locations
- Department of Surgery, Triemli Hospital, Zurich, Switzerland
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
1
2
Arm Description
bisacodyl 10mg twice daily from one day preoperative to day three postoperative
10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
Outcomes
Primary Outcome Measures
Time to recovery of gastrointestinal function, defined as the mean time to the occurrence of the following three events (GI-3): first flatus passed, first defecation and first solid food tolerated
Secondary Outcome Measures
Incidence of NGT reinsertion, duration of NGS reinsertion, incidence of postoperative vomiting and length of hospital stay
Full Information
NCT ID
NCT00509327
First Posted
July 30, 2007
Last Updated
July 30, 2007
Sponsor
University Hospital, Basel, Switzerland
1. Study Identification
Unique Protocol Identification Number
NCT00509327
Brief Title
Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery
Official Title
Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
April 2007
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University Hospital, Basel, Switzerland
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Postoperative bowel dysmotility is a frequent condition after colorectal surgery. The influence of colon stimulating laxatives have not been studied. This prospective, randomized, double blind, placebo controlled study assesses the influence of bisacodyl on postoperative bowel motility in patients undergoing elective colorectal surgery. The hypothesis of this trial was that bisacodyl has a beneficial effect on the duration of postoperative ileus.
Detailed Description
All adult (>18 years) patients admitted for elective colorectal resection were evaluated for eligibility.
Patients were randomized using a computer programme and received either 10mg of bisacodyl in non-transparent capsules or identical placebo capsules, containing glucosemonohydricum. The capsules were administered twice daily, starting one day before surgery and ending on postoperative day three.Patients and all involved medical personnel were blinded.
Bowel preparation was not routinely used in open surgery, whereas in patients undergoing laparoscopic resection two litres of sodium-sulfate / macrogol solution (Cololyt®, Spirig Pharma AG, Switzerland) was administered. Standard colorectal surgery was performed in all patients. In open surgery a midline incision was used for laparotomy. In laparoscopic resections a four-port technique with removal of the specimen through a small transverse incision in the lower abdomen was used. All patients received perioperative single shot antibiotics, cefuroxime 1.5 g and metronidazole 1g. Nasogastric tube (NGT) was scheduled to be removed at the end of surgery. Postoperative treatment was not changed during the study. All patients received postoperatively a basic analgesia of 500 to 1000 mg oral paracetamol every 6 h; additionally, metamizol was administrated intravenously or orally as needed.
The primary endpoint was the time to recovery of gastrointestinal function, defined as the mean time to the occurrence of the following three events (GI-3): first flatus passed, first defecation and first solid food tolerated. We did not include the presence of bowel movement, as they may be present before recovery of the colon due to small bowel activity24. Secondary endpoints were the incidence of NGT reinsertion, duration of NGS reinsertion, incidence of postoperative vomiting and length of hospital stay. Additionally, consumption of analgesics and pain, cramping and nausea scores (assessed with a visual analogue scale [VAS]) during the first 8 postoperative days were monitored. Other variables recorded were patients' demographics, use of epidural anaesthesia, type and duration of surgery and morbidity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Ileus
Keywords
postoperative ileus, colorectal surgery, bisacodyl, laxatives
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
bisacodyl 10mg twice daily from one day preoperative to day three postoperative
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
Intervention Type
Drug
Intervention Name(s)
bisacodyl
Intervention Description
10mg capsule twice daily from one day preoperatively to day three postoperatively
Intervention Type
Drug
Intervention Name(s)
glucosemonohydricum
Intervention Description
10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
Primary Outcome Measure Information:
Title
Time to recovery of gastrointestinal function, defined as the mean time to the occurrence of the following three events (GI-3): first flatus passed, first defecation and first solid food tolerated
Time Frame
10 days
Secondary Outcome Measure Information:
Title
Incidence of NGT reinsertion, duration of NGS reinsertion, incidence of postoperative vomiting and length of hospital stay
Time Frame
10 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
elective colorectal resection
age >18 years
Exclusion Criteria:
preoperatively planned stoma formation
emergency surgery
pregnancy
known hypersensitivity for bisacodyl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Urs Zingg, MD
Organizational Affiliation
department of Surgery, University Hospital Basel, Switzerland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Urs Metzger, Professor
Organizational Affiliation
Triemli Hospital, Zurich, Switzerland
Official's Role
Study Director
Facility Information:
Facility Name
Department of Surgery, Triemli Hospital, Zurich, Switzerland
City
Zurich
Country
Switzerland
12. IPD Sharing Statement
Learn more about this trial
Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery
We'll reach out to this number within 24 hrs